TAMA DC vaccine

TAMA DC vaccine is an experimental dendritic cell-based cancer immunotherapy that targets tumor-associated mitochondria antigens (TAMAs). Developed by researchers at the University of Pennsylvania, the vaccine is composed of dendritic cells loaded with mitochondria-enriched lysates derived from tumor cells. The rationale behind this approach is that somatic mitochondrial DNA abnormalities in cancer cells create unique or enriched antigens that can be targeted by the immune system. Preclinical studies, particularly in murine kidney tumor models (RENCA), have demonstrated that TAMA-based vaccination can generate prophylactic and therapeutic tumor-protective immunity. Its efficacy is significantly enhanced when combined with immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 antibodies, which remodel the tumor microenvironment to favor effector T cell infiltration and reduce immunosuppression.

Other names

tumor-associated mitochondria antigen dendritic cell vaccineDC-based tumor-associated mitochondria antigen immunotherapy